| 1 |
NCT02160717 |
Completed |
Risk of Diabetes in Young Turner Syndrome Patients |
|
|
Observational |
|
- Children's Hospital Medical Center, Cincinnati
- National Center for Advancing Translational Science (NCATS)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Beta-Cell Function measured as Disposition Index
|
120 |
Female |
6 Years to 22 Years (Child, Adult) |
NCT02160717 |
CCHMC-906
UL1TR000077 |
|
May 2014 |
June 2017 |
June 2017 |
June 11, 2014 |
August 23, 2017 |
|
- Children's Hospital Medical Center, Cincinnati
Cincinnati, Ohio, United States
|
| 2 |
NCT01668251 |
Unknown † |
Turner Syndrome Prenatal Diagnosis Study |
|
|
Observational |
|
- Seattle Children's Hospital
- Eli Lilly and Company
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Number of signs of Turner syndrome
- Growth
|
60 |
Female |
up to 3 Months (Child) |
NCT01668251 |
TS Prenatal Study |
|
January 2006 |
January 2017 |
January 2017 |
August 20, 2012 |
August 20, 2012 |
|
- Seattle Children's Hospital
Seattle, Washington, United States
|
| 3 |
NCT03185702 |
Recruiting |
Turner Syndrome Research Network Registry |
|
- Genetic: Research genetic tests
|
Observational |
|
- The University of Texas Health Science Center, Houston
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Bicuspid aortic valve and thoracic aortic aneurysm
- Health-related quality of life
|
200 |
Female |
Child, Adult, Senior |
NCT03185702 |
UTexas_Houston |
TRN |
August 28, 2015 |
January 1, 2025 |
January 1, 2030 |
June 14, 2017 |
March 22, 2018 |
|
- University of Texas Health Science Center Houston
Houston, Texas, United States
|
| 4 |
NCT00870220 |
Terminated |
Initiating Transdermal Estradiol Therapy in Turner's Syndrome |
|
- Drug: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
|
Interventional |
Phase 1 |
- University of Chicago
- Novo Nordisk A/S
- University of Michigan
- (and 5 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- The net change of height velocity between Group 2 and Group 3 and the net change in predicted height between Group 2 and Group 3.
- Plasma E2 level to document the dose-response effect of the applied prescription and uterine dimensions to quantitate the estrogenic effect on growth and development of the uterus.
|
1 |
Female |
138 Months to 13 Years (Child) |
NCT00870220 |
15327B |
|
April 2009 |
March 2011 |
March 2011 |
March 27, 2009 |
March 11, 2014 |
|
- University of Chicago
Chicago, Illinois, United States - John Hopkins University
Baltimore, Maryland, United States - University of Michigan
Ann Arbor, Michigan, United States
|
| 5 |
NCT03459651 |
Not yet recruiting |
Effect of Turner Syndrome on Number Sense |
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Single and multiple-operand addition and subtraction accuracy
- Single and multiple-operand addition and subtraction response time
|
250 |
Female |
6 Years to 40 Years (Child, Adult) |
NCT03459651 |
092883 |
|
June 1, 2018 |
March 31, 2023 |
March 31, 2023 |
March 9, 2018 |
April 17, 2018 |
|
- Center for Interdisciplinary Brain Sciences Research
Stanford, California, United States
|
| 6 |
NCT01367834 |
Completed
Has Results |
Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome |
|
|
Interventional |
Not Applicable |
- Rebecca Knickmeyer Santelli, PhD
- Pfizer
- University of North Carolina, Chapel Hill
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Total Brain Volume
- Volume of Brain Lobes (Occipital)
- White Matter Tracts (SLF)
- (and 6 more...)
|
17 |
Female |
11 Months to 13 Months (Child) |
NCT01367834 |
09-2171 |
|
May 2010 |
May 2014 |
May 2014 |
June 7, 2011 |
March 24, 2017 |
March 24, 2017 |
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
| 7 |
NCT03189160 |
Recruiting |
A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome |
|
- Biological: PEG-rhGH low dose
- Biological: PEG-rhGH high dose
- Other: Non-treatment control group
|
Interventional |
Phase 2 |
- GeneScience Pharmaceuticals Co., Ltd.
- Beijing Children's Hospital
- The First Affiliated Hospital with Nanjing Medical University
- (and 7 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of height standard deviation score before and after treatment (ΔHT SDS)
- Height Velocity
- ΔBA/ΔCA
- IGF-1(Insulin-like growth factor 1) SDS
|
180 |
Female |
2 Years to 18 Years (Child, Adult) |
NCT03189160 |
GenSci 032 CT |
|
March 2016 |
March 2018 |
|
June 16, 2017 |
December 12, 2017 |
|
- The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China - Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China - Jiangxi Provincial Children's Hospital
Nanchang, Jiangxi, China - (and 6 more...)
|
| 8 |
NCT01687842 |
Completed |
Social Cognition and Turner Syndrome |
|
- Other: Evaluation of 45,X Turner syndrome patients
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Overall score to the AQ (Autism Quotient) questionnaire.
- SRS (Social Reciprocity Scale), in comparison to the expected scores for the general population.
- Socio-cognitive profile and parent of origin of the intact X chromosome
|
25 |
Female |
8 Years to 18 Years (Child, Adult) |
NCT01687842 |
P110911
ID RCB 2012-A00488-35 |
COGNITUR |
March 2013 |
March 2017 |
March 2017 |
September 19, 2012 |
July 25, 2017 |
|
- Robert Debre Hospital
Paris, France
|
| 9 |
NCT00625001 |
Unknown † |
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Bone Mineral Density in columna lumbalis, collum femoris and distal ulnae Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.
|
54 |
Female |
18 Years and older (Adult, Senior) |
NCT00625001 |
1994/2424 |
|
November 1994 |
October 1996 |
June 2010 |
February 28, 2008 |
February 28, 2008 |
|
|
| 10 |
NCT00420654 |
Completed |
Growth Hormone Treatment of Women With Turner Syndrome |
|
- Drug: Growth Hormone
- Drug: Placebo
- Other: Healthy controls
|
Interventional |
Not Applicable |
- Britta E. Hjerrild
- University of Aarhus
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Body composition: fat mass and lean body mass
- Myocardial perfusion and glucose uptake, evaluated by positron emission tomography
- Heart function evaluated by echocardiography (conventional and tissue doppler)
- (and 2 more...)
|
24 |
Female |
20 Years to 40 Years (Adult) |
NCT00420654 |
2005-BH-GH |
|
August 2007 |
September 2011 |
September 2011 |
January 11, 2007 |
November 8, 2011 |
|
- Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital
Aarhus, DK, Denmark
|
| 11 |
NCT00624949 |
Unknown † |
Aortic Dimensions in Turner Syndrome |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Aortic diameter at 3 well-defined levels measured by MRI and ECHO
- 24hour ambulatory blood pressure
|
102 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT00624949 |
20010248 |
|
August 2003 |
June 2012 |
June 2012 |
February 28, 2008 |
February 28, 2008 |
|
|
| 12 |
NCT00877942 |
Completed |
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome |
|
|
Observational |
|
- University of North Carolina, Chapel Hill
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Brain volumes on MRI
- Brain volumes and DTI parameters
|
295 |
All |
up to 2 Years (Child) |
NCT00877942 |
K01MH083045-01
1K01MH083045-01 |
|
October 2006 |
May 2014 |
May 2014 |
April 8, 2009 |
May 2, 2014 |
|
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
| 13 |
NCT00825617 |
Completed |
Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy |
|
- Drug: Hormone replacement therapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- quantitative liver function tests
|
16 |
Female |
Child, Adult, Senior |
NCT00825617 |
19963561 |
|
October 1996 |
October 1999 |
June 2000 |
January 21, 2009 |
January 21, 2009 |
|
- Medical department M and Investigational Laboratories
Aarhus C, Jutland, Denmark
|
| 14 |
NCT00134745 |
Completed |
Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome |
|
|
Interventional |
Phase 4 |
- Line Cleemann
- Novo Nordisk A/S
- The County of Frederiksborg
- (and 4 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The size of the uterus evaluated by magnetic resonance (MR)-scan
- Bones evaluated by dual-energy X-ray absorptiometry (DEXA)-scan
- The diameter of the aortic root evaluated by MR-scan
- (and 4 more...)
|
43 |
Female |
10 Years to 25 Years (Child, Adult) |
NCT00134745 |
120895 |
|
June 2005 |
March 2013 |
March 2013 |
August 25, 2005 |
June 14, 2013 |
|
- Pediatric Unit, Hillerod Hospital
Hillerod, Frederiksborg County, Denmark
|
| 15 |
NCT01066052 |
Completed |
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years |
|
- Other: 0.15 IU/kg/day GH
- Other: 0.1 IU/kg/day GH
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Height gain at 2 year
- Tolerability criteria (Clinical): general and local tolerability (collection of AEs/SAEs)
- Tolerability criteria (Metabolic): HBA1c
- (and 4 more...)
|
64 |
Female |
up to 4 Years (Child) |
NCT01066052 |
GF 5834 |
|
February 1992 |
March 1999 |
August 2010 |
February 10, 2010 |
July 31, 2014 |
|
|
| 16 |
NCT00419107 |
Terminated |
Beta Cell Function in Women With Turner Syndrome |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
25 |
Female |
20 Years to 40 Years (Adult) |
NCT00419107 |
20040108 |
|
November 2004 |
|
January 2007 |
January 8, 2007 |
November 8, 2011 |
|
- Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital
Aarhus, Aarhus C, Denmark
|
| 17 |
NCT00004274 |
Completed |
Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome |
|
|
Interventional |
Not Applicable |
- National Institute of Neurological Disorders and Stroke (NINDS)
- Jefferson Medical College of Thomas Jefferson University
- Office of Rare Diseases (ORD)
|
NIH / Other |
- Primary Purpose: Treatment
|
|
260 |
Female |
8 Years to 12 Years (Child) |
NCT00004274 |
199/11680
TJU-11680 |
|
February 1990 |
|
|
October 19, 1999 |
June 24, 2005 |
|
- Jefferson Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 18 |
NCT00004275 |
Completed |
Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome |
|
- Drug: growth hormone
- Drug: oxandrolone
|
Interventional |
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- Jefferson Medical College of Thomas Jefferson University
- Office of Rare Diseases (ORD)
|
NIH / Other |
- Primary Purpose: Treatment
|
|
80 |
Female |
10 Years to 14 Years (Child) |
NCT00004275 |
199/11681
TJU-11681 |
|
October 1999 |
August 2007 |
|
October 19, 1999 |
September 10, 2008 |
|
- Jefferson Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 19 |
NCT00406926 |
Completed |
The Effect of Growth Hormone in Very Young Girls With Turner Syndrome |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Height at the end of two years in the study.
- Middle ear problems assessed every 4 months
- Hearing problems assessed annually
- Cognitive and behavioral development assessed annually
|
100 |
Female |
9 Months to 4 Years (Child) |
NCT00406926 |
2878
B9R-US-GDFG |
|
August 1999 |
|
August 2003 |
December 4, 2006 |
December 4, 2006 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Los Angeles, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Stanford, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Denver, Colorado, United States - (and 7 more...)
|
| 20 |
NCT00191113 |
Completed
Has Results |
Somatropin Treatment to Final Height in Turner Syndrome |
|
- Drug: Somatropin
- Drug: Ethinyl estradiol
- Drug: Medroxyprogesterone acetate
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population
- Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Last Measurement After Attainment of Final Height
- Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline, As-Treated Population
- (and 15 more...)
|
154 |
Female |
7 Years to 13 Years (Child) |
NCT00191113 |
817/4419
#817 B9R-CA-GDCT Core study
#4419 GDCT/1 Addenda |
GDCT |
February 1989 |
December 2007 |
December 2007 |
September 19, 2005 |
January 27, 2010 |
January 27, 2010 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Calgary, Alberta, Canada - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Edmonton, Alberta, Canada - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Vancouver, British Columbia, Canada - (and 11 more...)
|
| 21 |
NCT00029159 |
Completed |
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome |
|
- Drug: estrogen
- Drug: androgen
- Other: placebo
|
Interventional |
Phase 3 |
- Thomas Jefferson University
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Cognitive function in girls with Turner Syndrome
|
200 |
Female |
10 Years to 14 Years (Child) |
NCT00029159 |
R01NS032531 |
|
November 1992 |
January 2007 |
June 2012 |
January 9, 2002 |
June 5, 2012 |
|
- National Institutes of Health
Bethesda, Maryland, United States - Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 726
Philadelphia, Pennsylvania, United States
|
| 22 |
NCT00006334 |
Completed |
Turner Syndrome: Genotype and Phenotype |
|
|
Observational |
|
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
1017 |
All |
10 Years and older (Child, Adult, Senior) |
NCT00006334 |
000219
00-CH-0219 |
|
September 26, 2000 |
|
July 8, 2014 |
October 5, 2000 |
October 6, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 23 |
NCT00266656 |
Completed
Has Results |
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome |
|
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Most Mature Height Standard Deviation Score (SDS)
- Height SDS at Various Ages
- Age at Attainment of Tanner 2 Breast Development
- (and 6 more...)
|
69 |
Female |
4 Years to 20 Years (Child, Adult) |
NCT00266656 |
10088
B9R-US-GDGH |
|
December 2005 |
September 2015 |
September 2015 |
December 19, 2005 |
March 31, 2017 |
August 23, 2016 |
- Childrens Hospital of Los Angeles
Los Angeles, California, United States - Children's Hospital
Aurora, Colorado, United States - Connecticut Children's Medical Center
Hartford, Connecticut, United States - (and 6 more...)
|
| 24 |
NCT00097552 |
Completed |
A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
1696 |
Female |
up to 17 Years (Child) |
NCT00097552 |
85-036, Substudy 9 |
|
May 1997 |
July 2010 |
July 2010 |
November 25, 2004 |
November 14, 2012 |
|
|
| 25 |
NCT01410045 |
Active, not recruiting |
Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome |
- Turner Syndrome
- Ovarian Insufficiency
|
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
- Groupe Hospitalier Pitie-Salpetriere
- Cochin Hospital, India
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- the ovarian follicular density
- measure hormonal markers
|
47 |
Female |
1 Year to 25 Years (Child, Adult) |
NCT01410045 |
P081204 |
CRYO-X0 |
January 2011 |
January 16, 2014 |
February 2031 |
August 4, 2011 |
March 19, 2018 |
|
- Hopital Bicetre
Kremlin-Bicetre, France
|
| 26 |
NCT00001253 |
Completed |
The Effects of Estrogen on Cognition in Girls With Turner Syndrome |
- Gonadal Dysgenesis
- Turner's Syndrome
|
- Behavioral: cognitive tests and scales
|
Interventional |
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
950 |
All |
Child, Adult, Senior |
NCT00001253 |
900123
90-CH-0123 |
|
May 1990 |
|
March 2004 |
November 4, 1999 |
March 4, 2008 |
|
- National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States
|
| 27 |
NCT01813630 |
Active, not recruiting |
A Clinical Study to Assess the Efficacy and Safety of DA-3002 |
|
- Drug: DA-3002
- Drug: Genotropin®
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Annualized height velocity(cm/year) after 52 weeks
- Changes in height standard deviation score after 52 weeks
- Changes in bone maturation(changes in bone ages/changes in chronological age)
- (and 2 more...)
|
58 |
All |
2 Years to 12 Years (Child) |
NCT01813630 |
DA3002_TS_III |
|
February 2013 |
May 2018 |
|
March 19, 2013 |
September 20, 2017 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 28 |
NCT00001221 |
Completed |
Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome |
- Gonadal Dysgenesis
- Turner's Syndrome
|
- Drug: Growth Hormone (Humatrope)
|
Interventional |
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
160 |
Female |
Child, Adult, Senior |
NCT00001221 |
870152
87-CH-0152 |
|
September 1987 |
|
September 2003 |
November 4, 1999 |
March 4, 2008 |
|
- National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States
|
| 29 |
NCT01518036 |
Completed |
Use of Somatropin in Turner Syndrome |
- Genetic Disorder
- Turner Syndrome
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Final height in cm
- Ratio between change in bone age and change in chronological age
- Age at onset of puberty
- Adverse events
|
57 |
Female |
2 Years to 11 Years (Child) |
NCT01518036 |
GHTUR/BPD/1 |
|
September 14, 1987 |
April 11, 2004 |
April 11, 2004 |
January 25, 2012 |
February 28, 2017 |
|
- Novo Nordisk Investigational Site
Crawley, United Kingdom
|
| 30 |
NCT01419249 |
Completed
Has Results |
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study |
- Idiopathic Growth Hormone Deficiency
- Turner Syndrome
|
|
Interventional |
Phase 4 |
- Merck KGaA
- Merck Serono S.A., Geneva
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Change From Baseline in Height at Year 1
- Change From Baseline in Height Standard Deviation Score (SDS) at Year 1
- Height Velocity Standard Deviation Score (SDS) at Year 1
- (and 2 more...)
|
458 |
All |
up to 18 Years (Child, Adult) |
NCT01419249 |
EMR 200104_010 |
|
September 2011 |
October 2012 |
October 2012 |
August 18, 2011 |
January 16, 2014 |
January 16, 2014 |
- Hospital de Niños Ricardo Gutiérrez
Buenos Aires, Argentina - Hospital de Pediatria Garrahan
Buenos Aires, Argentina - Hospital de Niños de la Santisima Trinidad
Cordoba, Argentina - (and 28 more...)
|
| 31 |
NCT01734486 |
Completed |
Growth Response in Girls With Turner Syndrome |
- Genetic Disorder
- Turner Syndrome
|
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Height gain, SDS (Standard Deviation Score)
- Height gain in cm
- Height
- Bone maturation
|
31 |
Female |
Child, Adult, Senior |
NCT01734486 |
GHTUR/F/3 |
|
September 23, 1996 |
May 21, 2003 |
May 21, 2003 |
November 27, 2012 |
February 28, 2017 |
|
- Novo Nordisk Investigational Site
Besancon, France - Novo Nordisk Investigational Site
Bordeaux, France - Novo Nordisk Investigational Site
Dunkerque, France - (and 12 more...)
|
| 32 |
NCT01710696 |
Completed |
Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome |
- Genetic Disorder
- Turner Syndrome
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pubertal stage assesed by Tanner score
- FSH (Follicle Stimulating Hormone) levels
- Height velocity
- (and 2 more...)
|
50 |
Female |
Child, Adult, Senior |
NCT01710696 |
GHTUR/E/2 |
|
July 23, 1998 |
July 26, 2004 |
July 26, 2004 |
October 19, 2012 |
February 28, 2017 |
|
- Novo Nordisk Investigational Site
Alicante, Spain - Novo Nordisk Investigational Site
Badajoz, Spain - Novo Nordisk Investigational Site
Baracaldo, Spain - (and 25 more...)
|
| 33 |
NCT01518062 |
Completed |
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome |
- Genetic Disorder
- Turner Syndrome
|
- Drug: somatropin
- Drug: oestrogen
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Final height
- Height velocity (cm/year)
- Ratio between change in bone age and change in chronological age
- (and 2 more...)
|
65 |
Female |
2 Years to 11 Years (Child) |
NCT01518062 |
GHTUR/BPD/5-13 |
|
November 1989 |
September 2003 |
September 2003 |
January 25, 2012 |
January 18, 2017 |
|
- Novo Nordisk Investigational Site
Alphen a/d Rijn, Netherlands
|
| 34 |
NCT00443144 |
Completed |
D3-GHR Polymorphism and Turner Syndrome |
- Turner Syndrome
- Short Stature
|
- Drug: recombinant human growth hormone
|
Observational |
|
- University Hospital Tuebingen
|
Other |
|
|
|
Female |
38 Months to 14 Years (Child) |
NCT00443144 |
TS-TUE-FH1 |
|
May 2005 |
April 2007 |
May 2007 |
March 5, 2007 |
December 3, 2015 |
|
- University-Children's Hospital
Tübingen, Germany
|
| 35 |
NCT00013546 |
Completed |
Hormone Replacement Therapy to Treat Turner Syndrome |
- Osteoporosis
- Turner's Syndrome
|
|
Interventional |
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
92 |
Female |
Child, Adult, Senior |
NCT00013546 |
010114
01-CH-0114 |
|
March 2001 |
|
December 2002 |
March 21, 2001 |
March 4, 2008 |
|
- National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States
|
| 36 |
NCT03181230 |
Recruiting |
Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome |
- Turner Syndrome
- Turner Syndrome Mosaicism, 45, X/46, XX or XY
- Turner Syndrome Mosaicism 46,X,I(X)(Q10)/45,X
- Turner Syndrome Karyotype 46,X With Abnormal Sex Chromosome , Except I(Xq)
|
|
Observational |
|
- University of Colorado, Denver
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Peak oxygen consumption
- Quality of Life
- Percent body fat
- Insulin resistance (IR)
|
60 |
Female |
12 Years to 21 Years (Child, Adult) |
NCT03181230 |
17-0142
UL1TR001082 |
|
May 26, 2017 |
May 31, 2018 |
June 30, 2022 |
June 8, 2017 |
October 5, 2017 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
| 37 |
NCT02795000 |
Active, not recruiting |
Development a Predictive Nomogram for Primary Ovarian Insufficiency |
- Primary Ovarian Insufficiency
|
|
Observational |
|
- Guangzhou University of Traditional Chinese Medicine
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Draw the Primary Ovarian insufficiency normogram
- Verify and evaluate the evaluation of Primary Ovarian insufficiency normogram
|
260 |
Female |
18 Years to 42 Years (Adult) |
NCT02795000 |
2014KT1165 |
|
October 2016 |
May 2018 |
July 2018 |
June 9, 2016 |
April 10, 2018 |
|
- Guangdong provicial hospital of Chinese Medicine
GuangZhou, Guangdong, China
|
| 38 |
NCT02794948 |
Completed |
Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency |
- Primary Ovarian Insufficiency
|
- Other: Chinese medicine granules (HuYang Yang Kun Formula)
- Dietary Supplement: dehydroepiandrosterone
|
Interventional |
Phase 1
Phase 2 |
- Guangzhou University of Traditional Chinese Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Anti-Mullerian hormone
- Follicle stimulating hormone
- Estrogen
- (and 2 more...)
|
48 |
Female |
18 Years to 40 Years (Adult) |
NCT02794948 |
YN2014TS06 |
|
April 2016 |
December 2017 |
December 2017 |
June 9, 2016 |
April 10, 2018 |
|
- Guangzhou University of Traditional Chinese Medicine
Guangzhou, Guangdong, China
|
| 39 |
NCT00001343 |
Completed |
The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome |
- Dwarfism
- Turner's Syndrome
|
- Drug: Humatrope
- Drug: Oxandrolone
|
Interventional |
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
80 |
Female |
10 Years to 14 Years (Child) |
NCT00001343 |
930054
93-CH-0054 |
|
December 11, 1992 |
|
October 10, 2007 |
November 4, 1999 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 40 |
NCT00256126 |
Completed
Has Results |
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® |
- Growth Hormone Deficiency
- Turner Syndrome
|
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1
- Change From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 1
- Change From Baseline in Fasting Glucose Levels at Month 1
- (and 3 more...)
|
318 |
All |
2 Years to 16 Years (Child) |
NCT00256126 |
24531 |
|
May 31, 2005 |
September 30, 2007 |
September 30, 2007 |
November 21, 2005 |
March 20, 2018 |
March 20, 2018 |
- Local Medical Information Office
Buenos Aires, Argentina - Local Medical Information Office
Sydney, Australia - Local Medical Information Office
Vienna, Austria - (and 10 more...)
|
| 41 |
NCT03033277 |
Recruiting |
Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI) |
- Primary Ovarian Insufficiency
|
- Biological: Placebo transplantation
- Biological: HUC-MSCs transplantation
|
Interventional |
Phase 1
Phase 2 |
- Chinese Academy of Sciences
- The Third Affiliated Hospital of Guangzhou Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of mature follicle
- Follicle-stimulating hormone (FSH) serum level
- Estradiol (E2) serum level
- (and 4 more...)
|
320 |
Female |
20 Years to 40 Years (Adult) |
NCT03033277 |
Multi-cited POI Recovery |
|
February 2016 |
April 2017 |
July 2018 |
January 26, 2017 |
January 26, 2017 |
|
- Institute of Zoology, Chinese Academy of Sciences.
Beijing, Beijing, China
|
| 42 |
NCT00837616 |
Completed
Has Results |
Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism |
- Turner Syndrome
- Hypogonadism
- Premature Ovarian Failure
|
- Drug: 17 B estradiol orally
- Drug: 17 B estradiol
|
Interventional |
Phase 4 |
- Nemours Children's Clinic
- Genentech, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Weight From Baseline at 12 Months
- Change in Body Mass Index From Baseline at 12 Months
- Change in Percent Fat Mass From Baseline in 12 Months
- (and 8 more...)
|
41 |
Female |
13 Years to 20 Years (Child, Adult) |
NCT00837616 |
908-M01 |
|
January 2009 |
June 2012 |
December 2012 |
February 5, 2009 |
March 27, 2014 |
February 10, 2014 |
- Nemours Children's Clinic
Jacksonville, Florida, United States - Jefferson Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania, United States - University of Chile/Clinica las Condes
Santiago, Chile
|
| 43 |
NCT00250250 |
Completed |
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the local tolerability of an individualised dose of ZOMACTON 10 mg administered by ZomaJet Vision X
|
27 |
All |
3 Years to 17 Years (Child) |
NCT00250250 |
FE999905 CS002 |
|
October 2005 |
March 2006 |
August 2006 |
November 8, 2005 |
May 20, 2011 |
|
- Faculty Hospital Olomouc, Children's Clinic, Endocrinology Outpatient Department, I.P.Pavlova str. 6,
Olomouc, Czech Republic - Faculty Hospital Kralovske Vinohrady, Children's Clinic, Vinohradska str. 159
Prague 10, Czech Republic - Masaryk Hospital Usti nad Labem, Children's Clinic, Building D2, Endocrinology Outpatient Department, Socialni pece 12a
Usti nad Labem, Czech Republic - (and 3 more...)
|
| 44 |
NCT02250456 |
Recruiting |
AVAST Anomalies Vasculaires Associées au Syndrome de Turner (Vascular Abnormalities Associated With Turner Syndrome) |
- Turner Syndrome
- Peripheral Angiopathy
- Vascular Malformation
- Lymphedema
|
|
Observational |
|
- University Hospital, Strasbourg, France
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Collection of clinical events and systematized vascular ultrasound explorations
|
125 |
Female |
18 Years and older (Adult, Senior) |
NCT02250456 |
5545 |
AVAST |
July 2013 |
July 2024 |
July 2024 |
September 26, 2014 |
March 22, 2018 |
|
- Service de Chirurgie et Médecine Vasculaire, CHU Jean Minjoz
Besancon, France - Service d'Angiologie, CHU Bocage
Dijon, France - Service de gynécologie, Centre Médico Chirurgical Obstétrical, Hôpitaux Universitaires
Schiltigheim, France - (and 3 more...)
|
| 45 |
NCT03381300 |
Recruiting |
Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome |
- Fertility Preservation
- Ovarian Tissue Cryopreservation
- Turner Syndrome
- (and 2 more...)
|
- Procedure: Ovarian tissue cryopreservation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Live birth ratio (LBR) (main outcome)
- Number of primordial follicles (proximate)
- Patient's age versus LBR
- (and 3 more...)
|
100 |
Female |
2 Years to 18 Years (Child, Adult) |
NCT03381300 |
NL57738.000.16 |
|
January 1, 2018 |
January 1, 2021 |
January 1, 2071 |
December 21, 2017 |
January 23, 2018 |
|
- Radboud university medical center. Department Obstetrics & Gynaecology.
Nijmegen, Gelderland, Netherlands
|
| 46 |
NCT00121875 |
Terminated |
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature |
- Turner Syndrome
- Idiopathic Short Stature
|
|
Observational |
|
- Massachusetts General Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- to compare the effect of GH on IMCL content in the two subject groups (Turner syndrome vs. ISS)
- to assess the relationship of IMCL to IR-associated plasma markers in each groups
- to assess the relationship of IMCL to the effect of GH therapy in each groups
|
1 |
Female |
7 Years to 14 Years (Child) |
NCT00121875 |
2004P-002800
L3452n |
|
June 2005 |
|
December 2008 |
July 21, 2005 |
September 29, 2009 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 47 |
NCT00471731 |
Completed |
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure |
- Turner Syndrome
- Ovarian Failure, Premature
- Sex Chromosome Aberrations
- (and 2 more...)
|
|
Observational |
|
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
72 |
Female |
18 Years and older (Adult, Senior) |
NCT00471731 |
070145
07-EI-0145 |
|
May 7, 2007 |
|
November 13, 2014 |
May 10, 2007 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 48 |
NCT01678274 |
Unknown † |
Prospective Characterization of the Heart, Aorta and Blood Pressure in Turner Syndrome. Association With Aortic Dissection. |
- Turner Syndrome
- Aortic Aneurysm
- Ischemic Heart Disease
- (and 2 more...)
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Aortic dimensions
- Agatston score
- Segment involvement score
- (and 5 more...)
|
106 |
Female |
18 Years to 90 Years (Adult, Senior) |
NCT01678274 |
35202 |
TSCORII |
December 2013 |
March 2016 |
October 2016 |
September 3, 2012 |
May 24, 2016 |
|
- Department of Endocrinology and Internal medicine
Aarhus, Denmark
|
| 49 |
NCT00594763 |
Unknown † |
Venous Thrombosis in Turner Syndrome |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
|
60 |
Female |
18 Years and older (Adult, Senior) |
NCT00594763 |
20050045 |
|
June 2006 |
April 2008 |
April 2008 |
January 16, 2008 |
February 1, 2008 |
|
- Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital
Aarhus, Aarhus C, Denmark
|
| 50 |
NCT02322060 |
Unknown † |
In Vitro Activation of Dormant Follicles for Patients With Primary Ovarian Insufficiency |
- in Vitro Activation
- Dormant Follicle
- Primary Ovarian Insufficiency
|
- Procedure: Ovariotomy
- Procedure: Activate dormant follicles
- Procedure: Ovary tissue transplantation
|
Observational |
|
- The First Affiliated Hospital of Zhengzhou University
- Stanford University
- St. Marianna University School of Medicine
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Clinical pregnancy
- Follicle growth
|
100 |
Female |
18 Years to 39 Years (Adult) |
NCT02322060 |
RMCZZU-IVA |
IVADFPOI |
September 2014 |
November 2016 |
December 2016 |
December 22, 2014 |
January 13, 2015 |
|
- Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
|
Create an RSS feed from your search for:
Download the search results for: